Clinical trials: Chronic Hepatitis B Infections
Liver Cirrhosis, Hepatitis B, Chronic
Use of Gender, Age, Alfa-fetoprotein (AFP), and Des-gamma-carboxyprothrombin (PIVKA-II) or GAAD Score in Addition to Ultrasound for Surveillance of People At-risk for Developing Hepatocellular Carcinoma in Asia in Order to Detect Early Liver Cancer
HCC surveillance is currently limited by underutilization and the suboptimal performance of AFP. This prospective, single-arm study investigates whether the GAAD score (Gender, Age, AFP, and PIVKA-II) enhances HCC detection when…
- Conditions
- Liver Cirrhosis, Hepatitis B, Chronic, Hepatitis C, Chronic, Carcinoma, Hepatocellular
- Trial name
- STOPHCC-GAAD (NCT07298577)
- Testing
- PIVKA-II and GAAD score calculation
- Where
- Thailand
- Volunteers
- 2,100 people
- Sponsor
- Siriraj Hospital
Chronic HBV Infection
A Study to Evaluate the Antiviral Activity and Safety of HH-003 in Chronic Hepatitis B Subjects With Low-level Viremia
This is a multicenter, randomized, controlled Phase IIa study of HH-003 to evaluate the antiviral activity and safety in nucleos(t)ide analogues-treated chronic hepatitis B subjects with low-level viremia.
- Trial name
- NCT05734807
- Testing
- Nucleoside/nucleotide reverse transcriptase inhibitors (NrtIs), HH-003 and NrtIs, HH-003, NrtIs and PEG-IFN-α
- Where
- 8 sites in China
- Volunteers
- 74 people
- Sponsor
- Huahui Health
Hepatitis B
Baseline Investigation of Chronic Hepatitis B Viruses Infections: Who is Eligible for Treated Criteria
Through two-stage stratified cluster sampling, investigators studied the antiviral treatment rate and the main factors affecting the antiviral treatment in community chronic HBV infection-related liver disease population.
- Trial name
- NCT04264312
- Where
- 11 sites in China
- Volunteers
- 76,220 people
- Sponsor
- Wu Jiang
Liver Failure
The Efficacy and Safety of Entecavir Treatment of Patients With Acute on Chronic Hepatitis B Liver Failure
To evaluate therapeutic efficacy and predicting factors of entecavir for treating patients with acute on chronic hepatitis B liver failure (ACHBLF).
- Trial name
- NCT01254994
- Testing
- entecavir, Traditional comprehensive medical treatment
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Sun Yat-sen University
Chronic Hepatitis B
Prospective Study In Noninvasive Evaluation of Hepatic Fibrosis in Chronic Hepatitis B
The aim of our study is to evaluate liver fibrosis using biochemical markers, FibroScan, and radiology methods in patients with chronic hepatitis B in mainland China.
- Trial name
- NCT01679769
- Where
- China
- Volunteers
- 818 people
- Sponsor
- Peking University First Hospital
Hepatitis B, Chronic
Improved Sensitivity Detection of Serum HBsAg and HBsAg Reversion
The goal of this observational study is to learn about the HBsAg reversion rate at 48 weeks off treatment in HBsAg-negative patients by HBsAg NEXT assay which has improved sensitivity compared to current ARCHITECT HBsAg Assay.
- Trial name
- NCT06550622
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Huashan Hospital
Chronic Hepatitis B, Nonalcoholic Fatty Liver Disease
Follow-up of Chronic Hepatitis B Patients With Comorbid Nonalcoholic Fatty Liver Disease
The purpose of this study is to determine the disease progression in CHB/NAFLD compared with CHB and NAFLD including liver cirrhosis, cirrhotic complications and hepatocellular carcinoma (HCC).
- Trial name
- NCT02863757
- Where
- China
- Volunteers
- 1,500 people
- Sponsor
- Humanity and Health Research Centre
Hepatitis B, Chronic
Nabi-HB Administered Subcutaneously in Patients With Hepatitis B Virus Post Liver Transplantation
A phase 3, multicenter, open label study to assess the safety and efficacy of Nabi-HB, administered subcutaneously in patients with Hepatitis B Virus Associated Liver Disease who underwent liver transplantation.
- Trial name
- Nabi-HB-SC (NCT00800787)
- Testing
- Nabi-HB
- Sponsor
- Biotest Pharmaceuticals Corporation
Cancer, Liver Cirrhosis
Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer
To acquire blood samples from subjects for various purposes, including: i) determining the sensitivity and specificity of select DNA methylation markers for the detection of various types of cancer, ii) identifying benign…
- Conditions
- Cancer, Liver Cirrhosis, Chronic Hepatitis, Hepatitis B
- Trial name
- ELITE (NCT05181826)
- Testing
- Multi-analyte Blood Test
- Where
- 7 sites in United States
- Volunteers
- 1,200 people
- Sponsor
- Helio Genomics
Chronic Hepatitis b, ALT
Evaluation of Antiviral Indications on Chronic HBV Infection With Different Transaminase Levels
It remains unknown whether antiviral therapy is beneficial for chronic hepatitis B (CHB) with normal or mild ALT.The investigators aim to evaluate the antiviral indications combining liver biopsy and clinical parameters,and…
- Trial name
- NCT03740789
- Where
- China
- Volunteers
- 700 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Chronic Hepatitis B
The Optimizing Treatment of PegIFN Alfa in HBeAg-negative CHB Patients With Low Level HBsAg
As HBsAg clearance is uncommon in chronic hepatitis B (CHB) patients on nucleoside analogues (NAs) therapy. The purpose of this study is to optimize HBsAg clearance in CHB Patients with sequential treatment of pegylated…
- Trial name
- NCT02745704
- Testing
- Peginterferon alfa
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Chronic Hepatitis B
Activity of NCO-48 Fumarate in Treatment-Naive Adults With Chronic Hepatitis B
This is an open-label study evaluating multiple doses of NCO-48 Fumarate versus tenofovir alafenamide (TAF).
- Trial name
- NCT04629976
- Testing
- NCO-48 Fumarate 4 mg, NCO-48 Fumarate 20 mg, Tenofovir Alafenamide 25 mg
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Nucorion Pharmaceuticals, Inc.
Hepatitis B, Chronic
New Strategy Study of Functional Cure of Chronic Hepatitis B
As HBsAg clearance is uncommon in chronic hepatitis B (CHB) patients on nucleoside analogues (NAs) therapy. The purpose of this study is to optimize HBsAg clearance in CHB Patients with sequential treatment of pegylated…
- Trial name
- NCT02605252
- Testing
- Peginterferon alfa-2b
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Hepatitis B, Chronic
A Study of JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection
The purpose of this study is to evaluate the efficacy of 48-week study intervention with JNJ-73763989+JNJ-56136379+nucleos(t)ide analog (NA) regimen compared to NA alone assessed by HBsAg levels.
- Trial name
- NCT04129554
- Testing
- JNJ-73763989, JNJ-56136379, Entecavir (ETV) monohydrate
- Where
- 41 sites in Belgium, France and 5 more
- Volunteers
- 130 people
- Sponsor
- Janssen Sciences Ireland UC
Sequela of Chronic Liver Disease
ST-2; a Non-invasive Fibrosis Marker for Chronic Hepatitis B
IL-33 is a recently identified number of the IL-1 family. Hepatic over-expression of IL-33 has been recently linked to liver fibrosis. ST-2 exerts pro-inflammatory effects of IL-33.
- Trial name
- NCT01633554
- Where
- Turkey (Türkiye)
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- Turkiye Yuksek Ihtisas Education and Research Hospital
Chronic Hepatitis B, Steatosis of Liver
Quantitative CT Imaging Parameters for Assessing Hepatic Steatosis in CHB
This study aims to evaluate diagnostic performance of CT attenuation parameters acquired using deep learning algorithm in assessing hepatic steatosis and fibrosis.
- Conditions
- Chronic Hepatitis B, Steatosis of Liver, Fibrosis and Cirrhosis of Liver
- Trial name
- NCT06616103
- Testing
- computerized tomography
- Where
- South Korea
- Volunteers
- 111 people
- Sponsor
- Seoul National University Hospital
Chronic Hepatitis B
Observational Study on Patients With Chronic Hepatitis B
The study was conducted to evaluate the effect of anti-viral treatment on long-term outcome on patients with chronic hepatitis B.
- Trial name
- NCT02167503
- Where
- 14 sites in China
- Volunteers
- 10,000 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Hepatitis B, Chronic
A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection
The purpose of this study is to establish the dose-response relationship for antiviral activity of 3 dose levels of JNJ-73763989+nucleos(t)ide analog (NA) and to evaluate the efficacy of combination regimens of JNJ-73763989+NA…
- Trial name
- REEF-1 (NCT03982186)
- Testing
- JNJ-73763989, JNJ-56136379, Nucleos(t)ide Analog (NA)
- Where
- 108 sites in United States, Belgium and 17 more
- Volunteers
- 471 people
- Sponsor
- Janssen Sciences Ireland UC
Chronic Hepatitis b
Off-therapy Response After Stopping Entecavir or Tenofovir
Pegylated-interferon (Peg-IFN) α-2a, entecavir (ETV) and tenofovir disoproxil fumarate (TDF) are current recommended first-line antiviral therapies for chronic hepatitis B (CHB).
- Trial name
- NCT03042481
- Where
- Taiwan
- Volunteers
- 400 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Carcinoma, Hepatocellular
Atezolizumab Plus Bevacizumab With HCC and HBV Infection
This is a single-arm clinical trial. The main objective is to determine the efficacy of atezolizumab+bevacizumab therapy in patients with advanced hepatocellular carcinoma and with chronic hepatitis B virus infection.
- Trial name
- NCT04180072
- Testing
- Atezolizumab, Bevacizumab
- Where
- 7 sites in Taiwan
- Volunteers
- 51 people
- Sponsor
- National Health Research Institutes, Taiwan
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.